David Z.I. Cherney

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack et al. · New England Journal of Medicine · 2020 · 1.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation · 2013 · 1.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt, Michael Szarek, Bertram Pitt et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +17

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Cardiovascular Diabetology · 2014 · 469 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

David Z.I. Cherney, Bernard Zinman, Silvio E. Inzucchi et al. · The Lancet Diabetes & Endocrinology · 2017 · 373 citations

Medicine, Endocrinology, Pharmacology +17